Arthur L. Burnett, II, MD, MBA, told Urology Times that a review of this year’s sexual dysfunction abstracts reveals several important themes in sexual medicine, including hypogonadism and Peyronie’s disease.
“The topic of male hypogonadism and testosterone therapy remains in mainstream discussion, with studies further defining at-risk populations and risk factors for testosterone deficiency as well as examining long-term effects of testosterone therapy on sexual function, urinary function and prostate health, and cardiovascular health,” said Dr. Burnett, professor of urology at Johns Hopkins University, Baltimore.
“For Peyronie’s disease, treatment with intralesional collagenase clostridium histolyticum (XIAFLEX) has been further evaluated with reports on real-world experiences that heighten understanding of both its therapeutic role and outcomes,” he added.
Below are the key sexual dysfunction abstracts from this year, according to Dr. Burnett:
PD50-02: Effects of long-term testosterone undecanoate injections (TU) on urinary and sexual function in hypogonadal men: real-life data from a controlled registry study
PD50-03: Cardiovascular events and prostate cancer diagnoses in men treated with testosterone replacement therapy
PD45-02: Impact of number of cycles of Collagenase Clostridium Histolyticum on outcomes in patients with Peyronie’s disease